Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by First Light Asset Management LLC

First Light Asset Management LLC lessened its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 21.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 398,855 shares of the company’s stock after selling 107,367 shares during the period. Structure Therapeutics accounts for approximately 1.0% of First Light Asset Management LLC’s investment portfolio, making the stock its 26th biggest holding. First Light Asset Management LLC’s holdings in Structure Therapeutics were worth $10,817,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Foresite Capital Management VI LLC bought a new position in shares of Structure Therapeutics during the fourth quarter valued at approximately $11,390,000. Boothbay Fund Management LLC grew its stake in Structure Therapeutics by 147.0% during the 4th quarter. Boothbay Fund Management LLC now owns 83,148 shares of the company’s stock worth $2,255,000 after buying an additional 49,485 shares during the last quarter. Virtus ETF Advisers LLC increased its position in Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after buying an additional 455 shares during the period. Silverarc Capital Management LLC lifted its stake in Structure Therapeutics by 116.1% in the fourth quarter. Silverarc Capital Management LLC now owns 152,395 shares of the company’s stock valued at $4,133,000 after buying an additional 81,879 shares during the last quarter. Finally, Rock Springs Capital Management LP boosted its holdings in shares of Structure Therapeutics by 1.6% during the fourth quarter. Rock Springs Capital Management LP now owns 1,080,963 shares of the company’s stock valued at $29,316,000 after acquiring an additional 17,053 shares during the period. Institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on GPCR. William Blair started coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating on the stock. Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Trading Up 0.4 %

NASDAQ:GPCR opened at $23.74 on Monday. The company has a 50-day moving average of $20.17 and a 200-day moving average of $27.71. Structure Therapeutics Inc. has a twelve month low of $13.22 and a twelve month high of $62.74. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -32.08 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, research analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.